Cargando…
Should we screen for the sexually-transmitted infection Mycoplasma genitalium? Evidence synthesis using a transmission-dynamic model
There is increasing concern about Mycoplasma genitalium as a cause of urethritis, cervicitis, pelvic inflammatory disease (PID), infertility and ectopic pregnancy. Commercial nucleic acid amplification tests (NAATs) are becoming available, and their use in screening for M. genitalium has been advoca...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5700964/ https://www.ncbi.nlm.nih.gov/pubmed/29170443 http://dx.doi.org/10.1038/s41598-017-16302-8 |
_version_ | 1783281229628440576 |
---|---|
author | Birger, Ruthie Saunders, John Estcourt, Claudia Sutton, Andrew John Mercer, Catherine H. Roberts, Tracy White, Peter J. |
author_facet | Birger, Ruthie Saunders, John Estcourt, Claudia Sutton, Andrew John Mercer, Catherine H. Roberts, Tracy White, Peter J. |
author_sort | Birger, Ruthie |
collection | PubMed |
description | There is increasing concern about Mycoplasma genitalium as a cause of urethritis, cervicitis, pelvic inflammatory disease (PID), infertility and ectopic pregnancy. Commercial nucleic acid amplification tests (NAATs) are becoming available, and their use in screening for M. genitalium has been advocated, but M. genitalium’s natural history is poorly-understood, making screening’s effectiveness unclear. We used a transmission-dynamic compartmental model to synthesise evidence from surveillance data and epidemiological and behavioural studies to better understand M. genitalium’s natural history, and then examined the effects of implementing NAAT testing. Introducing NAAT testing initially increases diagnoses, by finding a larger proportion of infections; subsequently the diagnosis rate falls, due to reduced incidence. Testing only symptomatic patients finds relatively little infection in women, as a large proportion is asymptomatic. Testing both symptomatic and asymptomatic patients has a much larger impact and reduces cumulative PID incidence in women due to M. genitalium by 31.1% (95% range:13.0%-52.0%) over 20 years. However, there is important uncertainty in M. genitalium’s natural history parameters, leading to uncertainty in the absolute reduction in PID and sequelae. Empirical work is required to improve understanding of key aspects of M. genitalium’s natural history before it will be possible to determine the effectiveness of screening. |
format | Online Article Text |
id | pubmed-5700964 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-57009642017-11-30 Should we screen for the sexually-transmitted infection Mycoplasma genitalium? Evidence synthesis using a transmission-dynamic model Birger, Ruthie Saunders, John Estcourt, Claudia Sutton, Andrew John Mercer, Catherine H. Roberts, Tracy White, Peter J. Sci Rep Article There is increasing concern about Mycoplasma genitalium as a cause of urethritis, cervicitis, pelvic inflammatory disease (PID), infertility and ectopic pregnancy. Commercial nucleic acid amplification tests (NAATs) are becoming available, and their use in screening for M. genitalium has been advocated, but M. genitalium’s natural history is poorly-understood, making screening’s effectiveness unclear. We used a transmission-dynamic compartmental model to synthesise evidence from surveillance data and epidemiological and behavioural studies to better understand M. genitalium’s natural history, and then examined the effects of implementing NAAT testing. Introducing NAAT testing initially increases diagnoses, by finding a larger proportion of infections; subsequently the diagnosis rate falls, due to reduced incidence. Testing only symptomatic patients finds relatively little infection in women, as a large proportion is asymptomatic. Testing both symptomatic and asymptomatic patients has a much larger impact and reduces cumulative PID incidence in women due to M. genitalium by 31.1% (95% range:13.0%-52.0%) over 20 years. However, there is important uncertainty in M. genitalium’s natural history parameters, leading to uncertainty in the absolute reduction in PID and sequelae. Empirical work is required to improve understanding of key aspects of M. genitalium’s natural history before it will be possible to determine the effectiveness of screening. Nature Publishing Group UK 2017-11-23 /pmc/articles/PMC5700964/ /pubmed/29170443 http://dx.doi.org/10.1038/s41598-017-16302-8 Text en © The Author(s) 2017 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Birger, Ruthie Saunders, John Estcourt, Claudia Sutton, Andrew John Mercer, Catherine H. Roberts, Tracy White, Peter J. Should we screen for the sexually-transmitted infection Mycoplasma genitalium? Evidence synthesis using a transmission-dynamic model |
title | Should we screen for the sexually-transmitted infection Mycoplasma genitalium? Evidence synthesis using a transmission-dynamic model |
title_full | Should we screen for the sexually-transmitted infection Mycoplasma genitalium? Evidence synthesis using a transmission-dynamic model |
title_fullStr | Should we screen for the sexually-transmitted infection Mycoplasma genitalium? Evidence synthesis using a transmission-dynamic model |
title_full_unstemmed | Should we screen for the sexually-transmitted infection Mycoplasma genitalium? Evidence synthesis using a transmission-dynamic model |
title_short | Should we screen for the sexually-transmitted infection Mycoplasma genitalium? Evidence synthesis using a transmission-dynamic model |
title_sort | should we screen for the sexually-transmitted infection mycoplasma genitalium? evidence synthesis using a transmission-dynamic model |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5700964/ https://www.ncbi.nlm.nih.gov/pubmed/29170443 http://dx.doi.org/10.1038/s41598-017-16302-8 |
work_keys_str_mv | AT birgerruthie shouldwescreenforthesexuallytransmittedinfectionmycoplasmagenitaliumevidencesynthesisusingatransmissiondynamicmodel AT saundersjohn shouldwescreenforthesexuallytransmittedinfectionmycoplasmagenitaliumevidencesynthesisusingatransmissiondynamicmodel AT estcourtclaudia shouldwescreenforthesexuallytransmittedinfectionmycoplasmagenitaliumevidencesynthesisusingatransmissiondynamicmodel AT suttonandrewjohn shouldwescreenforthesexuallytransmittedinfectionmycoplasmagenitaliumevidencesynthesisusingatransmissiondynamicmodel AT mercercatherineh shouldwescreenforthesexuallytransmittedinfectionmycoplasmagenitaliumevidencesynthesisusingatransmissiondynamicmodel AT robertstracy shouldwescreenforthesexuallytransmittedinfectionmycoplasmagenitaliumevidencesynthesisusingatransmissiondynamicmodel AT whitepeterj shouldwescreenforthesexuallytransmittedinfectionmycoplasmagenitaliumevidencesynthesisusingatransmissiondynamicmodel |